

Please try another search
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Linda R. McGoldrick | 70 | 2020 | Independent Non Executive Director |
Thomas Lonngren | 75 | 2018 | Independent Non-Executive Director |
Alan F. Schatzberg | 80 | - | Member of Scientific Advisory Network |
Paul Summergrad | - | - | Member of Scientific Advisory Network |
Thomas R. Insel | 72 | - | Member of Scientific Advisory Network |
Wayne Joseph Riley | 66 | 2021 | Independent Non-Executive Director |
Annalisa Lisa Mary Jenkins | 60 | 2018 | Independent Non-Executive Director |
Diego Pizzagalli | - | - | Member of Scientific Advisory Network |
Robert Dwyer McQuade | 68 | 2020 | Independent Non Executive Director |
Gul Dolen | - | - | Member of Scientific Advisory Network |
John Rush | - | - | Member of Scientific Advisory Network |
Kirk Rutter | - | - | Special Advisor of Patient Experience |
Kabir Kumar Nath | 61 | 2022 | CEO & Director |
David York Norton | 74 | 2018 | Independent Director |
Daphne Karydas | 52 | 2023 | Independent Director |
Gino Santini | 68 | 2024 | Independent Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review